9OED

Ab1999 in complex with HIV-1 Env RC1

This is a non-PDB format compatible entry.

Summary for 9OED

• Entry DOI: 10.2210/pdb9oed/pdb
• Related: 9O8M
• EMDB information: 70395
• Descriptor: Ab1999 Fab Heavy Chain variable region, Ab1999 Fab Light Chain variable region, Envelope glycoprotein gp120, ... (9 entities in total)
• Functional Keywords: hiv-1 env, antibody, viral protein
• Biological source: Macaca mulatta (Rhesus monkey); More
• Total number of polymer chains: 8
• Total formula weight: 253559.22

Authors

Lin, Z.J.,Cui, J.,Du, J.,Relano-Rodriguez, I.,Escolano, A.,Pallesen, J. (deposition date: 2025-04-28, release date: 2026-02-11)

Primary citation

Relano-Rodriguez, I.,Du, J.,Lin, Z.J.,Kerwin, M.,Tarquis-Medina, M.,Urbano, E.,Cui, J.,Watkins, M.,Lavine, C.L.,Zhao, P.,Habib, R.,Agostino, C.,Ghosh, S.,Park, J.,Boroughs, C.,Walsh, A.A.,Melo, M.B.,Shukla, N.,Shaw, G.M.,Hahn, B.H.,Irvine, D.J.,Wells, L.,Weiner, D.B.,Seaman, M.S.,Kulp, D.W.,Veazey, R.S.,Pallesen, J.,Escolano, A.
Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.
Nat.Immunol., 2026

PubMed Abstract: Sequential immunization is a promising approach to elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 Envelope (Env). However, available protocols are inefficient and involve multiple immunizations over long periods of time. Here, we present WIN332, a new engineered Env immunogen that induces a new class of Asn332-glycan-independent antibodies to the conserved V3-glycan epitope of Env with low inhibitory activity indicative of a neutralization activity after a single bolus immunization in nonhuman primates. WIN332 binds to precursors of canonical human Asn332-glycan-dependent (type-I) V3-glycan bNAbs but also of a first-of-its-class Asn332-glycan-independent (type-II) V3-glycan bNAb. A single immunization elicits low inhibitory serum and monoclonal antibodies that are boosted and affinity matured with a heterologous immunogen. Electron microscopy polyclonal epitope mapping analysis of serum antibodies, antibody cloning and cryogenic electron microscopy analysis reveals that WIN332 elicits Asn332-glycan-independent antibodies with striking sequence and binding similarities with the most potent human type-I and type-II V3-glycan bNAbs. Thus, WIN332 is a promising vaccine candidate to streamline V3-glycan bNAb elicitation.

PubMed: 41634485
DOI: 10.1038/s41590-025-02408-z

Experimental method

ELECTRON MICROSCOPY (3.94 Å)